BioMarin has gained European Union approval for Palynziq (pegvaliase injection) for the rare metabolic condition phenylketonuria (PKU).
The EU decision comes a year after the FDA approval of the treatment, which is BioMarin’s follow-up to its existing PKU drug, Kuvan.
